PeriRx’s breach of licensing contract suit can’t prevail
13-01-2022
University of California granted fifth CRISPR patent
28-05-2019
Sundry Photography / Shutterstock.com
PeriRx has been hit with sanctions over its conduct after its breach of licensing suit failed in a patent licensing dispute against the University of California.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PeriRx, US District Court for the Eastern District of Pennsylvania, big pharma, patent licensing, University of California
